Vitaspring Biomedical Co Stock Net Income

VSBC Stock  USD 1.00  0.00  0.00%   
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess VitaSpring Biomedical's long-term financial health and intrinsic value.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

VitaSpring Biomedical Co Company Net Income Analysis

VitaSpring Biomedical's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

More About Net Income | All Equity Analysis

Current VitaSpring Biomedical Net Income

    
  1.26 M  
Most of VitaSpring Biomedical's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, VitaSpring Biomedical Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Competition

Based on the recorded statements, VitaSpring Biomedical Co reported net income of 1.26 M. This is 99.63% lower than that of the Healthcare sector and 98.2% lower than that of the Biotechnology industry. The net income for all United States stocks is 99.78% higher than that of the company.

VitaSpring Net Income Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses VitaSpring Biomedical's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of VitaSpring Biomedical could also be used in its relative valuation, which is a method of valuing VitaSpring Biomedical by comparing valuation metrics of similar companies.
VitaSpring Biomedical is currently under evaluation in net income category among its peers.

VitaSpring Fundamentals

About VitaSpring Biomedical Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze VitaSpring Biomedical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of VitaSpring Biomedical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of VitaSpring Biomedical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in VitaSpring Pink Sheet

VitaSpring Biomedical financial ratios help investors to determine whether VitaSpring Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in VitaSpring with respect to the benefits of owning VitaSpring Biomedical security.